Izvorni znanstveni članak

https://doi.org/10.20471/acc.2026.65.01.02

Serum Kallistatin as a Biomarker of Sepsis and Mortality in Geriatric Patients with Acute Kidney Injury

Bengu Tatar orcid.org/0000-0003-3787-1734 ; Department of Clinical Microbiology and Infectious Diseases, University of Health Sciences, Izmir Tepecik Education and Research Hospital, Izmir, Turkey *
Ilter Bozaci orcid.org/0000-0001-7535-9403 ; Department of Nephrology, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
Ali Serel ; Department of Internal Medicine, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
Merve Aktar ; Department of Internal Medicine, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
Guray Guvercin orcid.org/0000-0001-6909-0073 ; Department of Internal Medicine, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
Bulent Vatansever ; Department of Internal Medicine, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
Murat Karatas ; Department of General Surgery, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
Ahmet Aykas ; Department of General Surgery, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
Giray Bozkaya ; Department of Biochemistry, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
Erhan Tatar ; Department of Nephrology, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey

* Dopisni autor.

Sažetak

Kallistatin has beneficial effects on cardiorenal injury by inhibiting oxidative
stress, angiogenesis and inflammation. However, the role in geriatric patients
with acute kidney injury (AKI) has not been investigated in clinical studies. The
aim of this study was to evaluate the relationship among kallistatin, cardiovascular
biomarkers and mortality in geriatric patients with AKI and infection. In
this observational, longitudinal study, 104 geriatric patients (age >65 years) with
AKI were included. Serum kallistatin, NT-proBNP, troponin I and CK-MB were
measured at first admission. Patients were evaluated according to the infection
and/or sepsis status. The mean age of patients was 80±7.0 years. Twenty-
five (24%) AKI patients died during hospitalization. The nonsurvivor geriatric
patients with AKI were significantly older than survivors. Serum albumin and
kallistatin levels were significantly lower, however, NT-proBNP and serum urea
levels were significantly higher in nonsurvivors compared to survivors. Serum
kallistatin levels in patients with sepsis were lower than in those without sepsis
(10.2±3.9 vs. 17.4±2.5; p<0.001). The mortality rate was 4.6 higher in septic patients
(46% vs. 10%; p<0.001). Serum kallistatin (Exp(B): 0.83 (0.73-0.94; p<0.01)
and NT-proBNP (Exp(B): 1.001 (1.001-1.002); p<0.05) were independently associated
with mortality. Serum kallistatin and NT-proBNP levels were associated
with mortality of geriatric patients with AKI. In addition, the presence of sepsis
in AKI may be responsible for low serum kallistatin levels. Large-scale studies
are needed to clarify this issue.

Ključne riječi

Acute kidney injury; Geriatric patients; Kallistatin; Brain natriuretic peptide; Cardiovascular biomarkers; Sepsis, Mortality

Hrčak ID:

345826

URI

https://hrcak.srce.hr/345826

Datum izdavanja:

27.3.2026.

Podaci na drugim jezicima: hrvatski

Posjeta: 267 *